Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 8461-8470 Newer>

The Motley Fool July 18, 2005 W.D. Crotty	More Restructuring at HP? Rumors are flying. Is it time to buy? The stock's rise over the last three months probably already reflects investors' view on a restructuring, as a way to get HP's weak 5.5% operating margins rising.
The Motley Fool July 18, 2005 Tom Taulli	Traffix Craves Online Traffic It may be a small interactive marketing company, but Traffix's results are getting bigger. Investors, take note.
The Motley Fool July 18, 2005 Nathan Parmelee	A Giant Question for GE Its diversity and double-digit growth across the board are attractive to investors, but is the price right?
The Motley Fool July 18, 2005 Stephen D. Simpson	Bank of America's Unsightly Curve Sagging interest income hampers this otherwise healthy bank. While current conditions make these challenging times to own a bank stock, patient investors might want to consider picking up shares before the yield curve eventually improves.
The Motley Fool July 18, 2005 Stephen D. Simpson	J.B. Hunt Keeps On Trucking Results were sluggish for this overland shipping company, but it's still growing. Should it manage to live up to analysts' growth expectations, this stock could yet haul some reasonable gains for its investors.
The Motley Fool July 18, 2005 Stephen D. Simpson	Huaneng Power Browns Out High coal prices smack first-half earnings for this Chinese power company. Still, the stock does offer a dividend yield of more than 4%, and the long-term outlook for electricity demand in China has to be considered robust at this point.
The Motley Fool July 18, 2005 Stephen D. Simpson	Philips Stuck in Neutral The growth outlook for this diversified European company looks pretty feeble. But if Philips can get its growth back on track in the next year or so, the valuations today look somewhat reasonable.
The Motley Fool July 18, 2005 Stephen D. Simpson	Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky.
The Motley Fool July 18, 2005 Alyce Lomax	A Shinier Schwab After some tough years, Schwab shows more signs of a turnaround. Investors, take note.
The Motley Fool July 18, 2005 Stephen D. Simpson	Citigroup Still in Flux Second-quarter results were disappointing, but value might still lurk within. After all, value often seems to follow when most investors don't want anything more to do with a company or its stock.
<Older 8461-8470 Newer> Return to current articles.